I-Mab Biopharma (Shanghai) Co. Ltd., of Shanghai, said it entered a collaboration with Roche Holding AG, of Basel, Switzerland, to evaluate its CD73 antagonist, TJD-5, in combination with Tecentriq (atezolizumab). Roche will supply atezolizumab for use in clinical study, with rights generated in the study belonging jointly to the companies.